Safety and Efficacy of the Vascular Closure Device (Tonbridge) in Hemostasis Treatment of Femoral Artery Puncture

Ton-Bridge Medical Tech. Co., Ltd228 enrolled

Overview

The purpose of this study is to verify the safety and efficacy of the Vascular Closure Device (Tonbridge) in hemostasis treatment for femoral artery puncture.

This is a prospective, multicenter, randomized control, non-inferiority clinical trial carried out in 7 centers throughout China. 228 subjects with hemostasis of femoral artery puncture will be treated with the Vascular Closure Device (Tonbridge) or the EXOSEAL Vascular Closure Device (Codis Corporation). The primary objective of this study is to evaluate the safety and effectiveness of the vascular closure device in hemostasis treatment for femoral artery puncture.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

228

Conditions

Vascular Closure Endovascular Procedure Hemostasis Femoral Artery Puncture

Interventions

Vascular Closure Device (Tonbridge)DEVICE

Hemostasis treatment for femoral artery puncture with Vascular Closure Device (Tonbridge).

EXOSEAL Vascular Closure Device (Codis Corporation)DEVICE

Hemostasis treatment for femoral artery puncture with EXOSEAL Vascular Closure Device (Codis Corporation).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-80, male or non-pregnant female; * Subjects undergoing unilateral femoral artery retrograde puncture for angiography or interventional procedure; * Using guide sheath ≥5F to ≤8F, and length ≤12cm in angiography or interventional procedure; * Subjects or their legal guardians voluntarily participate in this study, can complete follow-ups, and sign the informed consent form. Exclusion Criteria: * Ipsilateral common femoral artery occlusion or lumen diameter \< 5mm; * Inability to walk; * Allergy to contrast media; * Allergy to PGA or PEG; subjects with a history of common femoral artery surgery, percutaneous transluminal angioplasty (PTA), stent implantation, or vascular graft; * Subjects with bleeding tendency, such as thrombocytopenia (platelet count \<100×109/L), hemophilia, von willebrand diseases, pre-procedure INR \>1.5, etc.; * Subjects have taken anticoagulants for a long term before the procedure and have blood coagulation disorders; * BMI \>40kg/m\^2; * Subjects receive thrombolytic therapy (such as streptokinase, urokinase, t-PA) within≤24 hours before vascular closure; * Local infections or skin infections of the investigational limb; * Subjects with target femoral artery dissection or aneurysm within 30 days before intervention procedure; * Subjects with puncture site have been punctured through the posterior wall of the femoral artery, or have been punctured several times (≥3 times), or have bleeding or hematoma on the femoral artery puncture site during the procedure; * Subjects with clinically significant peripheral vascular diseases (such as severe calcification, arteritis, stenosis, etc) near the puncture site; * Women who are pregnant or breastfeeding, OR men or women who plan to have a child in the next 6 months; * Subjects who are enrolled in other clinical trials and don't complete; * Subjects are considered not suitable for enrollment by the investigators.

Locations (7)

The First Affiliated Hospital of Wannan Medical College

Wuhu, Anhui, China

Nanyang Central Hospital

Nanyang, Henan, China

Puyang Oilfield General Hospital

Puyang, Henan, China

Henan Provincial People's Hospital

Zhengzhou, Henan, China

Outcomes

Primary Outcomes

Immediate hemostasis success rate

Immediate hemostasis success is defined as no significant blood oozing and no visible or palpable expanding or developing hematoma on femoral artery puncture site within 5 minutes, once completing the closure operation of femoral artery puncture site using vascular closure device.

Time frame: intra-procedure

Secondary Outcomes

Time to hemostasis

The time it takes (unit: minute) to reach no significant blood oozing and no visible or palpable expanding or developing hematoma on femoral artery puncture site, once completing the closure operation of femoral artery puncture site using vascular closure device.

Time frame: intra-procedure

Incidence of complications associated with femoral artery access

"Incidence of complications associated with femoral artery access" is the proportion of subjects with femoral artery access complications using the investigational device or the comparator.

Time frame: 30±7 days post-procedure

Incidence of device deficiency

Device deficiency is the unreasonable risk that may endanger human health and life safety under normal use of medical devices during clinical trials, such as labeling errors, quality problems and malfunctions, etc.

Time frame: intra-procedure

Incidence of adverse events (AE)

"Incidence of adverse events" is the proportion of subjects with adverse events using the investigational device or the comparator.

Time frame: 30±7 days post-procedure

Incidence of serious adverse events (SAE)

"Incidence of serious adverse events" is the proportion of subjects with serious adverse events using the investigational device or the comparator.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.